Halozyme Therapeutics Inc (HALO)
Gross profit margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Gross profit | US$ in thousands | 855,907 | 636,892 | 520,812 | 361,897 | 224,227 |
| Revenue | US$ in thousands | 1,015,320 | 829,253 | 660,116 | 443,310 | 267,594 |
| Gross profit margin | 84.30% | 76.80% | 78.90% | 81.64% | 83.79% |
December 31, 2024 calculation
Gross profit margin = Gross profit ÷ Revenue
= $855,907K ÷ $1,015,320K
= 84.30%
Based on the data provided, Halozyme Therapeutics Inc's gross profit margin has shown a declining trend over the years. In December 31, 2020, the gross profit margin stood at 83.79%, indicating a strong ability to generate profit from its core operations. However, this margin decreased to 81.64% by December 31, 2021, and further dropped to 78.90% by December 31, 2022.
By December 31, 2023, the gross profit margin fell even lower to 76.80%, suggesting potential challenges in maintaining profitability levels. The trend reversed in December 31, 2024, with a notable increase in the gross profit margin to 84.30%, signaling a potential improvement in the company's ability to generate profit from sales after a period of decline.
Overall, the fluctuation in Halozyme Therapeutics Inc's gross profit margin indicates the company's changing efficiency in managing production costs and pricing strategies. It would be essential for stakeholders to further investigate the factors driving these fluctuations to ensure sustained profitability and operational effectiveness.
Peer comparison
Dec 31, 2024